2024-09-07 - Analysis Report
##  MRK Stock Analysis Report

**Company:** Merck & Co., Inc. (MRK), a global pharmaceutical company known for its diverse portfolio of medicines and vaccines.

**Performance vs. S&P 500:**

* **Cumulative Return:** MRK: 52.93% vs. S&P 500 (VOO): 89.66%
* **Relative Performance:** MRK is underperforming S&P 500 by 36.73%. This represents 38.25% of the historical range of relative performance between the two assets.

**Recent Price Action:**

* **Closing Price:** $118.45
* **Moving Averages:**
    * 5-Day: $117.22
    * 20-Day: $114.88
    * 60-Day: $122.73

**Technical Indicators:**

* **RSI:** 81.9 (High) - Suggests the stock might be overbought and prone to correction.
* **PPO:** 0.74 (Positive) - Shows positive momentum, though high RSI might suggest a possible shift.
* **Delta_Previous_Relative_Divergence:** -6.71 (Negative) - Indicates a short-term downward trend.
* **Expected_Return:** 11.87% - This represents the estimated maximum 5-year return potential for the current investment.

**Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-05 | 2.15 | $16.11 B |
| 2024-05-03 | 1.88 | $15.78 B |
| 2023-11-03 | 1.87 | $15.96 B |
| 2023-08-07 | -2.35 | $15.04 B |
| 2024-08-05 | -2.35 | $15.04 B |

The latest earnings report for the quarter ending August 5, 2024, reported EPS of $2.15, exceeding analysts' expectations.  Revenue came in at $16.11 billion, also beating estimates. This positive performance highlights Merck's continued growth and resilience.

**Overall Analysis:**

* MRK is currently underperforming the S&P 500, but has shown recent earnings strength. 
*  Technical indicators suggest possible overbought conditions and a short-term downward trend.
*  However, strong earnings and a positive expected return suggest potential for future growth. 

**Conclusion:**

While MRK's recent performance hasn't matched the broader market, its strong earnings suggest a solid foundation for future growth. However, the current high RSI and negative short-term divergence indicators warrant caution.  Investors should carefully monitor MRK's performance and consider its potential correction before making any investment decisions. 
